Table 6.
Comparison of the occurrence of MACEs between groups
| Variable | Control group (n=55) | PCSK9 inhibitor group (n=55) | χ2 | P |
|---|---|---|---|---|
| Cardiovascular death | 0 | 0 | - | - |
| Nonfatal myocardial infarction | 5 (9.1) | 2 (3.6) | 1.373 | 0.241 |
| Nonfatal ischemic stroke | 4 (7.3) | 3 (5.5) | 0.153 | 0.696 |
| Hospitalization for unstable angina | 8 (14.5) | 3 (5.4) | 2.525 | 0.112 |
| Unplanned revascularization | 7 (12.7) | 4 (7.3) | 0.909 | 0.340 |
| Target lesion revascularization | 2 (3.6) | 0 | 2.037 | 0.154 |
| Revascularization of other lesions | 3 (3.4) | 1 (1.8) | 1.038 | 0.308 |
Note: All data are presented as n (%). Abbreviations: MACEs, major adverse cardiovascular events; PCSK9, proprotein convertase subtilisin/kexin 9.